• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sonendo, Inc. Reports First Quarter 2024 Financial Results and Announces Strategic Reset Priorities

    5/8/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care
    Get the next $SONX alert in real time by email

    Sonendo, Inc. (OTCQX:SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the first quarter ended March 31, 2024

    Recent Highlights

    • Recorded total revenue of $7.0 million for first quarter of 2024, exceeding previously issued guidance of $6.0 million; ending the quarter with installed base of 1,142 and achieved a healthy console backlog
    • Increased average procedure instrument selling price from $71.60 in the fourth quarter of 2023 to $75.00 in the first quarter of 2024 by limiting certain discount programs and focusing on utilization opposed to shipments. In the future quarters, we expect procedure instrument shipments to align with customer utilization
    • Announced strategic reset of commercial and operational priorities including commercial strategy, cash conservation, and margin expansion
    • Divested TDO practice management software segment in March 2024, resulting in a gain of $5.7 million
    • First quarter GAAP gross margin of 28%; non-GAAP gross margin of 30%, an improvement of more than 700 basis points over the first quarter of 2023
    • First quarter GAAP operating loss of $10.2 million; non-GAAP operating loss of $7.5 million, a 41% improvement over the first quarter of 2023
    • Raised 2024 full year revenue guidance range to $29 million to $31 million, from prior guidance of $28 million to $30 million

    "Building on our learnings over the past two years, Sonendo has embarked on a strategic reset to align key priorities for the long-term health of the Company," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have overhauled our go-to-market strategy, created efficiencies within the organization, and pivoted R&D efforts in order to drive commercial execution, cash conservation, and margin expansion. I am very encouraged by early indications of the plan's success demonstrated in the first quarter. The strategic reset has created a renewed energy within Sonendo, and I'm excited about the opportunity going forward."

    First Quarter 2024 Financial Results

    Except as otherwise indicated, the GAAP and non-GAAP financial measures presented in this press release exclude discontinued operations.

    Total revenue from continuing operations was $7.0 million for the first quarter of 2024, a decrease from $8.7 million for the first quarter of 2023. GentleWave console revenue was $1.8 million for the first quarter of 2024 compared to $2.0 million for the first quarter of 2023. Procedure instrument revenue was $4.2 million, a decrease from $5.7 million for the first quarter of 2023. Other product related revenue was $1.0 million for each of the first quarter of 2024 and 2023.

    Gross margin from continuing operations for the first quarter of 2024 was 28%, compared to 23% for the first quarter of 2023. During the first quarter of 2024, we recorded in cost of sales $0.1 million impairment charges of long-lived assets. Non-GAAP gross margin from continuing operations for the first quarter of 2024 was 30% compared to 23% for the first quarter of 2023. Non-GAAP gross margin excludes impairment of long-lived assets.

    Total operating expenses for the first quarter of 2024 were $12.3 million, compared to $17.0 million for the first quarter of 2023.

    Operating loss was $10.2 million for the first quarter of 2024, compared to $15.1 million for the first quarter of 2023. Non-GAAP operating loss was $7.5 million for the first quarter of 2024 compared to $12.8 million for the first quarter of 2023. Non-GAAP operating loss excludes stock-based compensation expense, depreciation and amortization expense and impairment of long-lived assets.

    Net loss from both continuing and discontinued operations was $6.8 million for the first quarter of 2024, including a $5.7 million gain from sale of our software business, compared to $15.4 million for the first quarter of 2023.

    Cash and cash equivalents and short-term investments as of March 31, 2024 totaled $33.6 million. During the first quarter of 2024, the company made $16.8 million principal repayments on the Perceptive term loan.

    2024 Financial Guidance

    The company expects total revenue for the full year of 2024 to be in the range of $29.0 million to $31.0 million, which excludes revenue from the discontinued operations.

    Webcast and Conference Call Information

    Sonendo will host a conference call to discuss the first quarter 2024 financial results after the market close on Wednesday, May 8, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4893 for international callers, using access code: 627665. Live audio of the webcast will be available on the "Investors" section of the company's website at: https://investor.sonendo.com. The webcast will be archived and available for replay for at least 90 days after the event.

    About Sonendo

    Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. In March 2024, Sonendo divested the TDO® Software segment by selling substantially all the assets and liabilities of TDO Software, Inc.

    For more information about Sonendo and the GentleWave System, please visit www.sonendo.com. To find a GentleWave doctor in your area, please visit www.gentlewave.com.

    Forward Looking Statements

    This press release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, express or implied forward-looking statements relating to the Company's anticipated business and financial performance on an on-going basis and Sonendo's 2024 financial guidance. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the "Risk Factors" set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

    Use of Non-GAAP Financial Measures

    Sonendo' financial results are prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). This press release and the reconciliation tables included in the financial schedules below include non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating loss (collectively, the "Non-GAAP measures"). Non-GAAP gross profit and non-GAAP gross margin exclude impairment of long-lived assets. Non-GAAP operating loss excludes, as applicable, stock-based compensation expense, depreciation and amortization and impairment of long-lived assets. Management believes that Non-GAAP measures are useful in helping identify the company's core operating performance and enables management to consistently analyze the period-to-period financial performance of the core business operations. Management also believes that Non-GAAP measures will enable investors to assess the company in the same way that management has historically assessed the company's operating results against comparable companies with conventional accounting methodologies. The company's definition for each of the Non-GAAP measures has limitations as an analytical tool and may differ from other companies reporting similarly named measures. Non-GAAP measures should not be considered measures of financial performance under GAAP, and the items excluded from such Non-GAAP measures should not be considered in isolation or as alternatives to financial statement data presented in the financial statements as an indicator of financial performance or liquidity. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.

    For a reconciliation of our Non-GAAP measures presented herein to GAAP measures, the most directly comparable GAAP financial measure, please see "Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin" and "Reconciliation of GAAP to Non-GAAP Operating Loss" in the financial schedules below.

    SONENDO, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share data)

     

     

     

    March 31,

     

    December 31,

     

     

    2024

     

     

    2023

     

     

     

    (Unaudited)

     

     

    ASSETS

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    18,580

     

     

    $

    14,009

     

    Short-term investments

     

     

    15,009

     

     

     

    32,773

     

    Accounts receivable, net

     

     

    4,176

     

     

     

    4,790

     

    Inventory

     

     

    12,116

     

     

     

    11,074

     

    Prepaid expenses and other current assets

     

     

    1,611

     

     

     

    1,969

     

    Current assets of discontinued operations

     

     

    1,162

     

     

     

    656

     

    Total current assets

     

     

    52,654

     

     

     

    65,271

     

    Property and equipment, net

     

     

    767

     

     

     

    461

     

    Operating lease right-of-use assets

     

     

    3,227

     

     

     

    2,703

     

    Other assets

     

     

    127

     

     

     

    128

     

    Non-current assets of discontinued operations

     

     

    —

     

     

     

    9,597

     

    Total assets

     

    $

    56,775

     

     

    $

    78,160

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable

     

    $

    916

     

     

    $

    1,142

     

    Accrued expenses

     

     

    2,737

     

     

     

    3,072

     

    Accrued compensation

     

     

    1,470

     

     

     

    2,413

     

    Operating lease liabilities

     

     

    1,172

     

     

     

    1,250

     

    Current portion of term loan

     

     

    10,800

     

     

     

    24,900

     

    Other current liabilities

     

     

    1,786

     

     

     

    1,844

     

    Current liabilities of discontinued operations

     

     

    73

     

     

     

    700

     

    Total current liabilities

     

     

    18,954

     

     

     

    35,321

     

    Operating lease liabilities, net of current

     

     

    1,888

     

     

     

    1,423

     

    Term loan, net of current

     

     

    10,911

     

     

     

    12,467

     

    Other liabilities

     

     

    491

     

     

     

    530

     

    Total liabilities

     

     

    32,244

     

     

     

    49,741

     

    Commitments and contingencies

     

     

     

     

    Stockholders' equity:

     

     

     

     

    Preferred stock, $0.001 par value; authorized —10,000,000 shares; issued and outstanding - none

     

     

    —

     

     

     

    —

     

    Common stock, $0.001 par value; authorized — 500,000,000 shares; issued and outstanding— 70,449,873 shares as of March 31, 2024 and 63,547,467 shares as of December 31, 2023

     

     

    70

     

     

     

    64

     

    Additional paid-in-capital

     

     

    461,237

     

     

     

    458,357

     

    Accumulated other comprehensive loss

     

     

    (1

    )

     

     

    11

     

    Accumulated deficit

     

     

    (436,775

    )

     

     

    (430,013

    )

    Total stockholders' equity

     

     

    24,531

     

     

     

    28,419

     

    Total liabilities and stockholders' equity

     

    $

    56,775

     

     

    $

    78,160

     

    SONENDO, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF

    OPERATIONS AND COMPREHENSIVE LOSS

    (unaudited)

    (In thousands, except share and per share data)

     

     

     

    Three Months Ended March 31,

     

     

    2024

     

     

    2023

     

    Revenue, net

     

    $

    7,047

     

     

    $

    8,678

     

    Cost of sales

     

     

     

     

    Product and service

     

     

    4,900

     

     

     

    6,700

     

    Impairment of long-lived assets

     

     

    146

     

     

     

    —

     

    Total cost of sales

     

     

    5,046

     

     

     

    6,700

     

    Gross profit

     

     

    2,001

     

     

     

    1,978

     

    Operating expenses:

     

     

     

     

    Selling, general and administrative

     

     

    10,061

     

     

     

    14,114

     

    Research and development

     

     

    2,189

     

     

     

    2,927

     

    Total operating expenses

     

     

    12,250

     

     

     

    17,041

     

    Operating loss

     

     

    (10,249

    )

     

     

    (15,063

    )

    Other expense, net:

     

     

     

     

    Interest and financing costs, net

     

     

    (1,940

    )

     

     

    (579

    )

    Loss before income tax expense

     

     

    (12,189

    )

     

     

    (15,642

    )

    Income tax expense

     

     

    —

     

     

     

    —

     

    Loss from continuing operations, net of tax

     

     

    (12,189

    )

     

     

    (15,642

    )

    Income from discontinued operations, net of tax

     

     

    5,427

     

     

     

    271

     

    Net loss

     

    $

    (6,762

    )

     

    $

    (15,371

    )

     

     

     

     

     

    Other comprehensive income (net of tax):

     

     

     

     

    Unrealized (loss) gain on short-term investments

     

     

    (12

    )

     

     

    56

     

    Comprehensive loss

     

    $

    (6,774

    )

     

    $

    (15,315

    )

    Net loss per share from continuing operations – basic and diluted

     

    $

    (0.13

    )

     

    $

    (0.16

    )

    Net income per share from discontinued operations – basic and diluted

     

    $

    0.06

     

     

    $

    0.00

     

    Net loss per share – basic and diluted

     

    $

    (0.07

    )

     

    $

    (0.16

    )

    Weighted-average shares outstanding – basic and diluted

     

     

    94,822,835

     

     

     

    93,391,444

     

    SONENDO, INC.

    RECONCILIATION OF GAAP TO NON-GAAP

    GROSS PROFIT AND GROSS MARGIN

    (unaudited, in thousands)

     

     

     

    Three Months Ended March 31

     

     

     

    2024

     

     

    2023

     

    Gross profit

     

    $

    2,001

     

     

    $

    1,978

     

    Gross margin

     

     

    28

    %

     

     

    23

    %

     

     

     

     

     

     

     

    Adjustments:

     

     

     

     

     

     

    Impairment of long-lived assets

     

     

    146

     

     

     

    —

     

    Non-GAAP gross profit

     

    $

    2,147

     

     

    $

    1,978

     

    Non-GAAP gross margin

     

     

    30

    %

     

     

    23

    %

    SONENDO, INC.

    RECONCILIATION OF GAAP TO NON-GAAP

    OPERATING LOSS

    (unaudited, in thousands)

     

     

     

    Three Months Ended March 31

     

     

     

    2024

     

     

    2023

     

    GAAP operating loss

     

    $

    10,249

     

     

    $

    15,063

     

    Adjustments:

     

     

     

     

     

    Stock based compensation:

     

     

     

     

     

    Included in cost of sales

     

     

    (302

    )

     

     

    (139

    )

    Included in selling, general and administrative

     

     

    (1,724

    )

     

     

    (1,540

    )

    Included in research and development

     

     

    (495

    )

     

     

    (224

    )

    Depreciation and amortization

     

     

     

     

     

    Included in cost of sales

     

     

    —

     

     

     

    (177

    )

    Included in selling, general and administrative

     

     

    (55

    )

     

     

    (150

    )

    Included in research and development

     

     

    —

     

     

     

    (31

    )

    Impairment of long-lived assets

     

     

     

     

     

    Included in cost of sales

     

     

    (146

    )

     

     

    —

     

    Non-GAAP operating loss

     

    $

    7,527

     

     

    $

    12,802

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240508041029/en/

    Get the next $SONX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SONX

    DatePrice TargetRatingAnalyst
    3/12/2024Buy → Hold
    Stifel
    1/31/2022$6.90Equal-Weight
    Morgan Stanley
    11/23/2021$16.00Buy
    Stifel
    11/23/2021$15.00Buy
    B of A Securities
    11/23/2021$30.00Buy
    Goldman Sachs
    11/23/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $SONX
    Financials

    Live finance-specific insights

    See more
    • Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

      Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca

      11/11/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. to Report Third Quarter 2024 Financial Results on November 12, 2024

      Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2024 after the market close on Tuesday, November 12th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 788725. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on th

      10/29/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

      Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Generated $8.3 million total revenue for second quarter of 2024 and carried over a healthy console backlog for the second straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 37.5% and 40.7%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $6.7 million and adjusted EBITDA (non-GAAP) loss to $5.7 million, a 61% and 55% improv

      8/7/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sonendo, Inc. Announces $5.0 Million Private Placement

      Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock, resulting in gross proceeds of $5.0 million (the "Private Placement"). New and existing investors, including certain directors and officers of the Company, participated in the financing. Sonendo intends to use the proceeds from the financing to expand commercial programs to drive revenue growth, continue executing ongoing business restructuring activities to further reduce operating expenses and accelerate the path to positive adjusted EBITDA and operating cash flow, to retain senior leadership and key emplo

      5/1/25 6:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2024. Quarterly Highlights Generated $8.3 million total revenue for the fourth quarter 2024; Drove substantial 1,570 and 1,260 basis points of GAAP and adjusted (non-GAAP) gross margin expansion for the fourth quarter 2024 to 41.1% and 41.3%, respectively, as compared to the prior year quarter; Significantly reduced GAAP operating loss to $5.6 million and adjusted EBITDA (non-GAAP) loss to $4.7 million for the fourth quarter 2024, an improvement of 45.2% and 45.0%, respectively,

      3/26/25 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Reports Third Quarter 2024 Financial Results

      Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Generated $8.0 million total revenue for the third quarter of 2024 and carried over a double-digit console backlog for the third straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 41.2% and 42.6%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $7.5 million and adjusted EBITDA (non-GAAP) loss to $5.1 million, a 57% and

      11/12/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sonendo downgraded by Stifel

      Stifel downgraded Sonendo from Buy to Hold

      3/12/24 7:33:34 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on Sonendo with a new price target

      Morgan Stanley initiated coverage of Sonendo with a rating of Equal-Weight and set a new price target of $6.90

      1/31/22 7:34:46 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Sonendo with a new price target

      Stifel initiated coverage of Sonendo with a rating of Buy and set a new price target of $16.00

      11/23/21 7:43:50 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Leadership Updates

    Live Leadership Updates

    See more

    $SONX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SONX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SONX
    SEC Filings

    See more

    $SONX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sonendo Strengthens Leadership With Key Strategic Appointments

      John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of Marketing John McGaugh Promoted to Senior Vice President of Operations Sonendo, Inc. (OTCQX:SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of John Bostjancic as Chief Financial Officer, the appointment of Robert Guyatt as Senior Vice President of Marketing, and the promotion of John McGaugh to Senior Vice President of Operations. "Sonendo is embarking on a reset strategy to drive fundamental change within the organization," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have fil

      6/5/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo Announces New Partnership Agreements with Two Leading Specialty DSOs to Expand Access to the GentleWave® Procedure for Elevated Root Canal Treatment

      The Partnership Agreements Aim to Increase the Number of Endodontic Practices Offering the GentleWave System Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the signing of two new strategic partnership agreements with the country's leading endodontic dental service organizations (DSOs) to expand patient access to a best-in-class root canal experience. As a result of these partnerships, the GentleWave System with CleanFlow™ Technology, which offers a less invasive and less painful alternative to traditional root canal therapy, will be available in more endodontic offices nationwide. Sonendo previously announced the a

      10/4/23 8:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08

      Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo's Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company. The awards were granted under Sonendo's 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"), which was adopted on March 2, 2023 and provides for the granting of equity awards to prospective employees of Sonendo under NYSE Listing Rule 303A.08. The restricted stock unit awards vest over a four-year p

      9/26/23 8:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Mcgaugh John P. bought $11,545 worth of shares (116,500 units at $0.10), increasing direct ownership by 47% to 363,797 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/23/24 6:05:19 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Bergheim Olav bought $49,504 worth of shares (520,000 units at $0.10) (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/17/24 2:30:11 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Pudipeddi Vamsi Mohan Raj bought $47,000 worth of shares (500,000 units at $0.09), increasing direct ownership by 27% to 2,374,498 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/14/24 5:18:33 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sonendo Inc.

      SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

      11/14/24 4:40:34 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sonendo Inc.

      SC 13G - Sonendo, Inc. (0001407973) (Subject)

      11/14/24 1:23:43 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sonendo Inc. (Amendment)

      SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

      2/14/24 5:15:11 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form D filed by Sonendo Inc.

      D - Sonendo, Inc. (0001407973) (Filer)

      5/12/25 1:21:37 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Sonendo Inc.

      10-K - Sonendo, Inc. (0001407973) (Filer)

      3/26/25 4:06:45 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Sonendo Inc.

      EFFECT - Sonendo, Inc. (0001407973) (Filer)

      2/28/25 12:15:03 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sr. VP Operations Mcgaugh John P. was granted 500,000 shares, increasing direct ownership by 142% to 852,896 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:48:44 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Bostjancic John J. was granted 600,000 shares, increasing direct ownership by 83% to 1,320,000 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:46:24 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • President and CEO Bergheim Bjarne was granted 1,600,000 shares, increasing direct ownership by 85% to 3,488,518 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:42:53 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care